Targeted Phototherapy for Malignant Pleural Mesothelioma: Near-Infrared Photoimmunotherapy Targeting Podoplanin
Open Access
- 20 April 2020
- Vol. 9 (4), 1019
- https://doi.org/10.3390/cells9041019
Abstract
Malignant pleural mesothelioma (MPM) has extremely limited treatment despite a poor prognosis. Moreover, molecular targeted therapy for MPM has not yet been implemented; thus, a new targeted therapy is highly desirable. Near-infrared photoimmunotherapy (NIR-PIT) is a recently developed cancer therapy that combines the specificity of antibodies for targeting tumors with toxicity induced by the photoabsorber after exposure to NIR-light. In this study, we developed a new phototherapy targeting podoplanin (PDPN) for MPM with the use of both NIR-PIT and an anti-PDPN antibody, NZ-1. An antibody–photosensitizer conjugate consisting of NZ-1 and phthalocyanine dye was synthesized. In vitro NIR-PIT-induced cytotoxicity was measured with both dead cell staining and luciferase activity on various MPM cell lines. In vivo NIR-PIT was examined in both the flank tumor and orthotopic mouse model with in vivo real-time imaging. In vitro NIR-PIT-induced cytotoxicity was NIR-light dose dependent. In vivo NIR-PIT led to significant reduction in both tumor volume and luciferase activity in a flank model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). The PDPN-targeted NIR-PIT resulted in a significant antitumor effect in an MPM orthotopic mouse model (p < 0.05, NIR-PIT group versus NZ-1-IR700 group). This study suggests that PDPN-targeted NIR-PIT could be a new promising treatment for MPM.This publication has 50 references indexed in Scilit:
- A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin AntibodyThe Journal of Immunology, 2013
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Numb controls E-cadherin endocytosis through p120 catenin with aPKCMolecular Biology of the Cell, 2011
- Value of D2-40 in the Differential Diagnosis of Pleural Neoplasms With Emphasis on Its Positivity in Solitary Fibrous TumorApplied Immunohistochemistry & Molecular Morphology, 2010
- Malignant mesotheliomaBritish Medical Bulletin, 2010
- Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cellsCarcinogenesis: Integrative Cancer Research, 2009
- Podoplanin is a Better Immunohistochemical Marker for Sarcomatoid Mesothelioma Than CalretininThe American Journal of Surgical Pathology, 2008
- Molecular analysis of the pathophysiological binding of the platelet aggregation‐inducing factor podoplanin to the C‐type lectin‐like receptor CLEC‐2Cancer Science, 2007
- Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domainBiochemical and Biophysical Research Communications, 2006
- Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patientsCancer Science, 2006